Pharmafile Logo

News and Press Releases

PTC Therapeutics to Participate at Upcoming Investor Conferences

4 November 2024 -- New Jersey, US -- PTC Therapeutics, Inc today announced that the company will present a company overview at the following conferences: UBS Global Healthcare ConferenceWednesday, Nov....

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: November 4, 2024

PTC Therapeutics
info@ptcbio.com
PTC Therapeutics Inc. 100 Corporate Court South Plainfield, NJ 07080-2449

Travere Therapeutics to Present at Upcoming Investor Conferences

4 November 2024 -- California, US -- Travere Therapeutics, Inc today announced that company management will present in the following upcoming investor conferences in November: Guggenheim Securities Healthcare Innovation ConferenceMonday, November 11,...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 4, 2024

Travere Therapeutics
3611 Valley Centre Drive, Suite 300 San Diego, CA 92130

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

1 October 2024 -- New Jersey, US -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: October 1, 2024

PTC Therapeutics
info@ptcbio.com
PTC Therapeutics Inc. 100 Corporate Court South Plainfield, NJ 07080-2449

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Milestone triggers payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb in March 2024, and...

Category: Other, Pharmaceutical
Posted: September 27, 2024

PureTech Health
info@puretechhealth.com
PureTech Health 6 Tide Street Boston, MA 02210

CARBOGEN AMCIS Announces Two Successful FDA Inspections at its Manufacturing Sites in Neuland and Aarau, Switzerland

23 July 2024 -- Bubendorf, Switzerland -- Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of...

Category: BioManufacturing, Other, Pharmaceutical
Posted: July 23, 2024

CARBOGEN AMCIS
info@carbogen-amcis.com
Hauptstrasse 171 CH-4416 Bubendorf Switzerland

Certa Therapeutics Receives EU Orphan Designation for FT011, a GPR68 Inhibitor Being Developed as an Anti-Fibrotic Treatment for Systemic Sclerosis

22 July 2024 -- Melbourne, Australia -- Certa Therapeutics, a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the European Medicines Agency...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: July 22, 2024

Certa Therapeutics
info@certatherapeutics.com
Level 9, 31 Queen Street Melbourne VIC 3000 Australia

FDA and CluePoints Sign New 3 Year Cooperative Research and Development Agreement to Assess Data Quality using Statistical Modelling and Machine Learning

FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials 5 June 2024 -- Pennsylvania, US -- CluePoints, providers...

Category: Biotechnology, Pharmaceutical
Posted: June 5, 2024

CluePoints
contact@cluepoints.com
1000 Continental Drive, Suite 240, King of Prussia, PA 19406

Successful Conclusion of London Biotechnology Show, Leaves Attendees Highly Satisfied

10 May 2024 -- London, UK -- The curtain has closed on the debut London Biotechnology Show 2024, leaving attendees thoroughly impressed by the seamless delivery of promised content and...

Category: Biotechnology
Posted: May 10, 2024

London Biotechnology Show
info@londonbiotechshow.com

Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration

Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours 5 March 2024 -- London, UK -- Ellipses Pharma, a global drug development...

Category: Drug Discovery
Posted: March 5, 2024

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry 23 November 2023 -- Cambridge, UK --...

Category: Clinical Trials
Posted: November 23, 2023

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

Signum Surgical Completes Clinical Trial for BioHealx

Galway based company compiling data for submission of a De Novo classification request to US FDA Novel surgical option for the treatment of anal fistula, a painful and debilitating colorectal...

Category: Clinical Trials
Posted: September 12, 2023

Signum Surgical
INFO@SIGNUMSURGICAL.COM
NEW DOCKS, THE DOCKS, GALWAY